is the premier journal dedicated to the scientific, medical, and psychosocial exploration of clinical cannabis, cannabinoids, and the biochemical mechanisms of endocannabinoids.The Journal publishes a broad range of human and animal studies including basic and translational research; clinical studies; behavioral, social, and epidemiological issues; and ethical, legal, and regulatory controversies.Tags: Essay On Cell Phones Being Allowed In SchoolEssay On Language Development In Early ChildhoodProblem Solving 2nd GradeFamous Dissertation QuotesHamburger EssayWebsite To Solve Any Math Problem
What little clinical research does exist is mostly limited to randomized controlled trials (RCTs) using synthetic cannabinoids or low quality and potency cannabis obtained from the federal government that is unrepresentative of the cannabis products used by millions of people every day.
Contributing to further confusion are historically contradictory messages coming from the scientific community on the true risks and benefits of cannabis consumption.
The preexisting anonymized data were obtained with user informed consent through the owner of the Releaf App, More Better, Ltd., and subject to an investigator confidentiality agreement.
The Releaf App patient education and cannabis treatment management tool was designed to track patient sessions and real-time cannabis use experiences in order to optimize the therapeutic effects of consuming cannabis, while minimizing negative side effects.
MAPS is working to demonstrate the safety and efficacy of smoked botanical marijuana as a prescription medicine for specific medical uses to the satisfaction of the U. NIDA's previous monopoly on the supply of marijuana for research and the DEA's prior refusal to allow researchers to grow their own has restricted medical marijuana research for decades. MAPS worked for over 22 years to obtain marijuana for medical marijuana drug development research, and the approval is a historic shift in federal policy.
Our efforts to initiate medical marijuana research have been hindered by the National Institute on Drug Abuse (NIDA) and the Drug Enforcement Administration (DEA) since our founding in 1986.Federal barriers and logistical challenges have hindered measurement of the real time effects from the types of cannabis products used medically by millions of patients in vivo.Between 06/06/2016 and 03/05/2018, 3,341 people completed 19,910 self- administrated cannabis sessions using the mobile device software, Releaf App to record: type of cannabis product (dried whole natural Cannabis flower, concentrate, edible, tincture, topical), combustion method (joint, pipe, vaporization), Cannabis subspecies (C. sativa), and major cannabinoid contents (tetrahydrocannabinol, THC; and cannabidiol, CBD), along with real-time ratings of health symptom severity levels, prior-to and immediately following administration, and reported side effects.From that time until the patient closes the session, they can enter multiple symptom severity levels as frequently as desired.For the current analyses, we include in our sample only patients entering starting symptoms greater than 0 and recording at least one symptom level within 90 minutes of starting the session; we use the last symptom level recorded within that timeframe as the ending symptom level.For example, whereas cannabis was once often and sometimes still is described as component cause of schizophrenia.Contradictory effects are often attributed to the distinction between what has been historically interpreted as cannabis’ harmful, psychoactive cannabinoid, tetrahydrocannabinol (THC), often described as providing the ‘high’ effects versus the therapeutic, non-psychoactive potential (sometimes described as a ‘miracle cure’ in the popular media) of cannabidiol (CBD).Our final sample includes 19,910 sessions and 3,341 patients who recorded at least one product characteristic in the Releaf App between 06/06/2016 and 03/05/2018.Because the entry of product characteristics is voluntary, the sample sizes used in our analyses vary depending on which product characteristics are included.The study began in January 2017 at Scottsdale Research Institute in Phoenix, Arizona, and completed its treatment phase in January 2019.We anticipate that the resulting paper will be submitted to journals for publication by June 2019.